Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11647MR)

This product GTTS-WQ11647MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11647MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15921MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ7593MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ9252MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ4401MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ14157MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ5804MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ6315MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ4263MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW